



## **Animal models of mucositis**

### **critical tools for advancing pathobiological understanding and identifying therapeutic targets**

Wardill, Hannah R; Tissing, Wim J E; Kissow, Hannelouise; Stringer, Andrea M

*Published in:*

Current Opinion in Supportive and Palliative Care

*DOI:*

[10.1097/SPC.0000000000000421](https://doi.org/10.1097/SPC.0000000000000421)

*Publication date:*

2019

*Document version*

Peer reviewed version

*Citation for published version (APA):*

Wardill, H. R., Tissing, W. J. E., Kissow, H., & Stringer, A. M. (2019). Animal models of mucositis: critical tools for advancing pathobiological understanding and identifying therapeutic targets. *Current Opinion in Supportive and Palliative Care*, 13(2), 119-133 . <https://doi.org/10.1097/SPC.0000000000000421>

This is the peer reviewed author accepted manuscript (post print) version of a published work that appeared in final form in:

Wardill, Hannah R, Tissing, Wim JE, Kissow, Hannelouise & Stringer, Andrea M 2019 'Animal models of mucositis: critical tools for advancing pathobiological understanding and identifying therapeutic targets', *Current opinion in supportive and palliative care* vol. 13, no. 2, pp. 119-133

This un-copied output may not exactly replicate the final published authoritative version for which the publisher owns copyright. It is not the copy of record. This output may be used for non-commercial purposes.

### **General Rights**

Copyright and moral rights for the publications made accessible in the Research Outputs Repository are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the persistent link identifying the publication in the Research Outputs Repository

If you believe that this document breaches copyright please [contact](#) us providing details, and we will remove access to the work immediately and investigate your claim.

## Animal models of mucositis: critical tools for advancing pathobiological understanding and identifying therapeutic targets

Wardill HR<sup>1,2</sup>, Tissing WJE<sup>2,3</sup>, Kissow H<sup>4</sup>, Stringer AM<sup>1,5</sup>

1. Adelaide Medical School, The University of Adelaide, Adelaide, Australia
2. Department of Paediatric Oncology and Haematology, University Medical Centre Groningen, Groningen, The Netherlands
3. Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
4. NNF Center of Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

Corresponding Author

Dr Andrea Stringer

Senior Research Fellow

Musculoskeletal Biology Research Group

School of Pharmacy and Medical Sciences

University of South Australia

North Terrace, Adelaide, SA, 5000, Australia

Ph: +61 8 8302 1760

Email: [andrea.stringer@unisa.edu.au](mailto:andrea.stringer@unisa.edu.au)

## Abstract

**Purpose of review:** Mucositis remains a prevalent, yet poorly managed side effect of anticancer therapies. Mucositis affecting both the oral cavity and gastrointestinal tract predispose to infection and require extensive supportive management, contributing to the growing economic burden associated with cancer care. Animal models remain a critical aspect of mucositis research, providing novel insights into its pathogenesis and revealing therapeutic targets. The current review aims to provide a comprehensive overview of the current animal models used in mucositis research.

**Recent findings:** A wide variety of animal models of mucositis exist highlighting the highly heterogeneous landscape of supportive oncology and the unique cytotoxic mechanisms of different anticancer agents. Golden Syrian hamsters remain the gold-standard species for investigation of oral mucositis induced by single-dose and fractionated radiation as well as chemoradiation. There is no universally accepted gold-standard model for the study of gastrointestinal mucositis, with rats, mice, pigs and dogs all offering unique perspectives on its pathobiology.

**Summary:** Animal models are a critical aspect of mucositis research, providing unprecedented insight into the pathobiology of mucositis. Introduction of tumour-bearing models, cyclic dosing scheduled, concomitant agents and genetically modified animals have been integral in refining our understanding of mucositis.

**Key words:** mucositis, animal models, preclinical, pathobiology

## **1.0 INTRODUCTION**

Mucositis remains a poorly managed side effect of almost all anticancer regimens, affecting 40-100% of people undergoing cancer therapy [1]. Although variations exist in its clinical presentation and histological features based on regional specific mechanisms, mucositis is largely underpinned by ulcerative lesions throughout the alimentary tract (mouth to anus). Mucositis affecting the oral cavity is fairly well defined, owing to the ease at which oral mucosa is accessed and the impact of resulting symptoms on people undergoing cancer therapy [2]. Gastrointestinal mucositis instead remains poorly understood [3], reflecting the difficulties in accessing the entire gastrointestinal tract [4] and the region-specific complexities of the gastrointestinal tract.

Despite decades of intensive research efforts, there remains no gold standard prophylactic or therapeutic intervention for mucositis, with the majority of treatments targeted at reducing the burden of symptoms and preventing secondary complications [5]. Given the logistical and ethical obstacles in collecting human biospecimens in supportive oncology, animal models remain heavily relied upon for continued research efforts aimed at understanding the pathobiology of mucositis, as well as assessing novel interventions. However, with mucositis an almost ubiquitous toxicity of cancer therapy, there are a wide variety of preclinical animal models tackling various aspects of mucositis development across a variety of clinical scenarios. These models each provide a unique perspective and highlight the need to select an appropriate model for the specific research question of interest. This, combined with increasingly sophisticated approaches, will see enhanced translation of preclinical findings with tangible impact for supportive oncology.

This review aims to provide a comprehensive overview of the current animal models used for mucositis research, highlighting their specific contribution to the field of supportive oncology and the major advances in the understanding of the pathogenesis of mucositis.

## **2.0 ANIMAL MODELS OF MUCOSITIS**

There are a number of animal models of mucositis that are readily available and easily established in most academic or scientific institutions. The major overarching benefit of developing such models is that although the intricate pathogenesis of mucositis is unclear, the causative factor leading to its development is clear. This homologous nature of mucositis models, defined by the fact that the cause of disease mimics the human condition, greatly increases the validity of these models and their associated findings. This has undoubtedly driven the large and increasing number of animal models used to understand the pathobiology of both oral and gastrointestinal mucositis caused by a variety of anticancer agents.

### **2.1 Small animal models of mucositis**

#### ***2.1.1 Oral mucositis***

In contrast to the clinical scenario, the investigation of oral mucositis using animal models is inherently challenging. This is primarily driven by the clear disparities in oral anatomy and physiology in rodents and humans [6], reflecting different dietary habits of each species (e.g. omnivores, herbivores, carnivores). Rodents exhibit a thin keratinised epithelium with low epithelial extensions, both of which minimise transport across the mucosa and reduce its sensitivity to overt

injury [6]. Unlike humans and other primates, rodents do not express glycogen-rich content in the cytoplasm of epithelial cells and exhibit higher antigen presenting cell (APC) density within the epithelium and lamina propria, indicating a local immune capacity overpowers an adaptive immune response [6]. Furthermore, rodents have been characterised to have low numbers of mast cells, only present in deeper tissue layers, suggesting lower communicative signaling between the apical surface of the mucosa and immune cells of the underlying tissue [6]. Salivary function has also been shown to differ between rodents and humans, with rodents not actively concentrating compounds (e.g. nitrate) in the saliva [7]. Collectively, these disparities affect the sensitivity of the oral mucosa in rodents to allergens, toxins and other pathogens and reduces the clinical presentation of mucositis-type lesions. In fact, it has been demonstrated that in rodents, the presentation of frank ulceration of the oral cavity is scarce with only histological evidence of reduced epithelial thickness indicative of mucositis development in many models [8]. This is further impacted by the relative difficulty in accessing the oral cavity of rodents without anaesthesia.

In order to overcome these obstacles, the **oral cheek pouch in hamsters** has provided a unique opportunity to study oral mucositis [9] (Table 1). Using this model, clinically-relevant mucositis has been induced using both chemotherapy [9] and radiotherapy [10], in which multiple doses are given on 3 separate days in addition to a physical insult used to replicate mechanical injury to the oral mucosa (e.g. eating, teeth rubbing). The hamster cheek pouch model is advantageous for a number of reasons [11]. Firstly, the hamster cheek consists of a renewing squamous epithelium, which is in many ways similar to the human mucosa. The cheek pouch is also large, facilitating examination and application of topical therapeutics. Furthermore, the oral bacterial flora is considered to parallel that of humans, dominated by gram-positive microbes [11].

The publication of this model revolutionised research approaches to mucositis development and prevention, with this model being instrumental in defining the universally accepted 5 phase pathobiological model of mucositis [12]. This model has been used in almost all iterations of cytotoxic therapy, including single dose radiation [13-15], fractionated radiation [10, 16] and combined chemoradiation [16, 17]; each developing clinically relevant features of oral mucositis (Table 1). For these reasons, it has been used countless times for the assessment of anti-mucositis agents, including epidermal growth factor (EGF) [18], transforming growth factor beta (TGF- $\beta$ ) [19], interleukin-11 (IL-11) [20], keratinocyte growth factor-1 (KGF-1, or palifermin) [13] and velifermin [10] (Table 1). Importantly, palifermin is now recommended by the Multinational Association for Supportive Care in Cancer (MASCC) for the prevention of mucositis in specific oncological cohorts [5], demonstrating the integral part preclinical models play in mucositis management.

Importantly, this model built upon the previously used **mouse model of radiation-induced mucositis** developed by Wolfgang Dorr and colleagues in the early 1990s [21, 22]. This model was one of the earliest models of mucositis, originally designed to study epithelial repopulation. The model is based upon an initial course of radiation to the snout of the mouse, given as a fractionated dose of 5 X 3 Gy/week for 1-2 weeks, followed by an additional top up dose localised to the lower tongue. This results in mucosal ulceration consistent with the clinical assessment criteria of the Radiation Therapy Oncology Group, and has therefore been used to study numerous interventions [21, 23, 24].

### **2.1.2 Gastrointestinal mucositis**

Immunological responses both locally and systematically, as well as the interaction with the resident microflora of the host, are key factors in the pathobiology of gastrointestinal mucositis [25]. Unfortunately, they too differ amongst species [26-28]. When considering this in combination with the highly heterogeneous landscape of supportive oncology, the difficulties in translating preclinical findings for mucositis interventions are not surprising. In saying this however, animal models have proven invaluable in shaping our understanding of the mechanisms that contribute to gastrointestinal mucositis and the identification of novel modifiable targets. This has certainly been the case over the past decade, with increasingly more sophisticated methods used to assess gastrointestinal function and carefully manipulate mechanisms of interest. These advances are now setting a precedent for more clinically translatable models, with clear overlap with the clinical scenario, thus aiding and accelerating the development of mucositis interventions.

Both rats and mice have been used to study gastrointestinal mucositis caused by a variety of anticancer agents (Table 2). Each model is unique to its host institution, however follows a fairly generic framework in which radiation or chemotherapy are delivered as a single dose or repeated exposures. Each method has advantages, with a single dose model enabling an unobstructed view of the time-course mucositis development [29]. Repeat exposure models certainly reflect the clinical scenario more adequately, however mechanistic interpretation is clouded by the confounding variables associated with innate and adaptive immunity and overlap between healing and insult [11].

### **2.1.2.1 Chemotherapy-induced gastrointestinal mucositis**

Methotrexate (MTX), 5-Fluorouracil (FU) and irinotecan remain the most commonly studied chemotherapeutic drugs in preclinical models of mucositis, owing to their high rates of gastrointestinal mucositis seen clinically. The **MTX-induced mucositis** model demonstrates a predictable, self-limiting mucositis time course. Using a single dose of 45 mg/kg – 60 mg/kg (intravenously), MTX induces clinically-relevant symptoms in male albino Wistar rats, including moderate diarrhoea, reduced food/water intake and weight loss, which peak at day 4 [30]. To date, this model has primarily been used to test a range of anti-mucositis interventions and nutritional strategies [30-34], as well as develop and validate the use of plasma citrulline as a biomarker [35]. Slight variations exist in this model, for example using an intraperitoneal dose of 20 µg/kg MTX (in Sprague Dawley rats) which, despite the extremely low dose, resulted in significant weight loss and histopathological features consistent with the clinic [36]. This model has primarily been used by Sukhotnik and colleagues to study enterocyte turnover [37], growth factors (e.g. glutamine, L-arginine and TGF-α) [38-40], nutritional supplements [41-43] and Wnt/β-catenin signaling in mucositis development [36] (Table 2). Unfortunately, these are yet to be translated to clinical practice guidelines.

The model of MTX mucositis has also been adapted for multiple chemotherapy dosing cycles, reflective of the clinic, with 1.5-7 mg/kg delivered on three consecutive days (subcutaneously)[44, 45]. This model induces clinically comparable symptoms of diarrhoea, reduced food intake and weight loss, peaking between days 6-8 (after first MTX dose). Preclinical results using this model have shown promise for anti-inflammatory agent, Olmesartan [45], and have highlighted overlapping mechanisms for mucositis and associated cachexia/anorexia [46].

Models of **5-FU** induced mucositis are also prevalent within the literature, however significant variation exists in the dosing schedules used, with doses ranging from 25 mg/kg to 450 mg/kg

(Table 2). In dark agouti rats, 150 mg/kg has been shown to induce intestinal injury and clinically relevant endpoints [47]. This model has been extensively used by Howarth et al. to study nutraceuticals designed to prevent mucositis [47-53], however there has been negligible translation of largely positive results. This group has also been the first to implement colonoscopic analysis of mucosal architecture in a model of colitis induced colorectal cancer [54], introducing a promising new method of mucositis assessment.

Cyclic models of 5-FU induced mucositis also exist, with 3-5 doses of 5-FU at ranges between 25-450 mg/kg. To date, two dose finding studies have been conducted to optimize this method in both male BALB/C and C57Bl6 mice [55, 56]. Unsurprisingly, weight loss and diarrhoea increased dose-dependently, with a concomitant increase in mortality. TUNEL and western blot demonstrated apoptosis in both the ileum and colon following 5-FU. In both studies five doses of 50-100 mg/kg (intraperitoneally) was optimal to induced clinically-relevant mucositis without unacceptable mortality. This contrast other models in which 5 cycles of 30 mg/kg 5-FU are administered to BALB/C mice; an approach recently used to investigate the benefits of probiotic supplementation [57, 58], Rebamipide (enteroprotective agent)[59], IL-1Ra [60], 5-HT<sub>3</sub> antagonists [61, 62] and minocycline [63]. These studies have together demonstrated the key roles and therapeutic potential of the microbiome, inflammatory signaling and oxidative stress in the development of 5-FU mucositis.

Similar protocols have also been used for *irinotecan*, in both rats and mice (Table 2). Irinotecan is associated with an early onset cholinergic diarrhoea and a late onset diarrhoea resulting from mucosal injury [29, 64]. Despite this, only some models routinely administer atropine (subcutaneously) with irinotecan. Animal models of irinotecan-induced mucositis were certainly the catalyst for understanding how the microbiome contributes to mucositis development, with bacterial  $\beta$ -glucuronidase integral in the metabolic processing of SN-38G (the inactive form of irinotecan) [65-67]. Dosing ranges vary significantly between studies, reflecting the variety of rodent strains used, but generally fall between 75-300 mg/ml, with peak mucositis occurring between days 3-5. Importantly, irinotecan must be administered in an acidic sorbitol lactic acid buffer for appropriate activation, with control animals receiving appropriate parallel dosing.

In addition to advancing our understanding of bacterial  $\beta$ -glucuronidase, models of irinotecan-induced mucositis have also been critical in shaping our understanding of intestinal barrier function in permitting mucositis development [68], and the interaction between innate immune receptors (e.g. toll-like receptors (TLR)) and mucositis severity [69, 70]. A number of interventions have also been studied in these models including St John's Wort [71-74], probiotic yeasts [75] and antioxidant agents targeting ROS production (e.g. fullerol) [76]. These studies have undoubtedly contributed to the current state of knowledge regarding irinotecan-induced mucositis, resulting in clear clinical strategies to prevent adverse toxicity. Of particular interest is the current FDA regulation requiring pharmacogenetic profiling of prospective patients for mutations in the UGT1A1 enzyme pathway [77, 78]. More recently, it has been demonstrated that irinotecan-induced gastrointestinal injury occurs simultaneously with markers of neuroinflammation, furthering our appreciation for the gut-brain axis in supportive oncology [69].

The last major class of chemotherapy used more commonly in preclinical models of gut dysfunction is *oxaliplatin*. This platinum-based chemotherapy is not typically associated with frank ulceration throughout the gastrointestinal tract, but is associated with severe gut dysfunction and peripheral neuropathy, suggesting alternative neural mechanisms are at play [79] (Table 2). Nurgali and colleagues developed a preclinical model of oxaliplatin-induced gut dysfunction, in

which six 3 mg/kg doses (over 2 weeks) induces weight loss, nausea (pica) and constipation in BALB/C mice [80]. Using this model, it has been demonstrated that oxaliplatin is associated with loss of enteric neurons, increasing the proportion of neuronal NO synthase-immunoreactive neurons and levels of mitochondrial superoxide and cytochrome c in the myenteric plexus [79-82]. Subsequent studies from this group have also demonstrated changes in TLR-expressing cells, microbiota composition and high-mobility group box 1 expression consistent with reduced transit time and gastrointestinal motility. These studies have led the way for motility-based assessment in gastrointestinal mucositis; a mechanism that has otherwise received very little attention.

Although these agents represent the majority of animal models dedicated to mucositis research, there remain a number of other studies focused on other anticancer agents. Doxorubicin-induced mucositis has been studied in dark agouti rats [83] and BALB/C mice [84, 85], as well as zebrafish [86]. Dosing ranges from 4-20 mg/kg, and is typically administered via two intraperitoneal injections on subsequent days (or separated by a few days). Variations of this model have shown key roles for TLR2/9 signaling, epithelial and mesenchymal gene signaling and sodium glucose transport mechanisms. Administration of doxorubicin in zebrafish offers a novel platform for high throughput analysis and simple genomic modification specifically tailored for toxicology studies [86]. For example, a green fluorescent kidney [Tg(wt1b:GFP)] and a red fluorescent skin transgenic zebrafish line [Tg(k18:dsred)] have been reported to evaluate the toxic effects on kidney and skin [87, 88].

### **2.1.2.2 Multimodal models**

Despite polypharmacy being routine clinical practice, the majority of models studying mucositis continue to be investigated in single drug injection models. Recently, there has been increasing research efforts diverted to developing multi-drug models of mucositis to facilitate and promote clinical translation. In 2016, Pereira and colleagues successfully induced mucositis in C57BL/6 mice via intraperitoneal injection of irinotecan (30-45 mg/kg) and 5-FU (25-50 mg/kg) [89]. They reported that the optimal dose concentration was 45 mg/kg and 37.5 mg/kg respectively (delivered on 4 consecutive days), with significant diarrhoea, body weight loss, intestinal damage, inflammatory cell infiltrate and cytokine production. Importantly, the dual treatment strategy induced mucositis to a greater extent to agents delivered in isolation, highlighting the critical need to develop more clinically relevant models of mucositis. Similarly, 5-FU and oxaliplatin have been studied in combination, reflecting their combined use in colorectal cancer, with evidence indicating therapeutic potential of IL-1R agonism [90] and probiotics [91] (Table 2).

### **2.1.2.3 Radiation-induced gastrointestinal mucositis**

While a number of models exist for chemotherapy-induced gastrointestinal mucositis, radiation models are less common. This is in stark contradiction to the clear impacts radiation has on intestinal function, both acutely and chronically, with many survivors suffering from rectal bleeding, faecal and mucous leaking, excessive gas and uncontrolled defecation years after treatment [92]. Paralleling the complex regimens for pelvic malignancies, in which daily irradiation occurs for several weeks is logistically cumbersome to model preclinically [93]. Much of our knowledge stems from models of total body irradiation with a limited number of high dose fractions given, with many animals not surviving past a few weeks [94]. This limits the study of long term gut dysfunction.

To overcome these limitations, a new model has been developed by Bull and colleagues, in which C57BL/6 mice are exposed to small-field radiation restricted to 1.5cm of the colorectum using a linear accelerator [95]. Each mouse receives 6-8 Gy, twice daily in two, three or four fractions. Validation of their model identified acute cell death in the colorectum, with associated crypt degeneration and immune cell infiltrate. Angiogenesis was elevated, paralleling clinical findings, with fibrosis observed 4 months after irradiation. This model allows for the longitudinal analysis of the mechanisms contributing to both acute and chronic toxicity resulting from pelvic irradiation, offering a more suitable platform for the study of interventions and development of biomarkers (Table 2).

#### **2.1.2.4 Tumour-bearing models**

It is clear that animal models of mucositis have improved our collective understanding of its pathobiology, leading to updated pathobiological models and in some cases, changes to clinical practice guidelines. However, in many respects they fail to adequately represent the entire clinical scenario. In contrast, tumour-bearing models offer a novel opportunity to assess mucositis in the presence of a neoplasm, and its associated effects on intestinal physiology and systemic signaling. They also offer an opportunity to mimic the immunological state of an oncology patient, who in many cases demonstrated compromised immunity and neutropenia. The presence of neutropenia in an individual with mucositis is clinically and mechanistically important, placing them at an increased risk of infectious complications and likely impacting on the severity of mucositis. As such, tumour-bearing models offer an opportunity to more accurately mimic the clinical scenario.

The ***Dark Agouti Mammary Adenocarcinoma (DAMA) rat model of mucositis*** is the most widely used tumour-bearing model in mucositis [29, 96]. Developed by Keefe and colleagues in the mid-1990's, this model overcomes the limitations of many models in that it simultaneously assesses mucositis and tumour cytotoxicity. Female DA rats are inoculated with an isogenic mammary adenocarcinoma, ~7-10 days prior to chemotherapy administration. Gibson et al, reported that mucositis was more severe in tumour-bearing animals, highlighting an important aspect of its pathobiology that would otherwise be overlooked in non-tumour bearing models [29] (Table 2).

This model has been used extensively over the past few decades to assess the efficacy of various anti-mucositis agents including palifermin/velofermin [97-99], IL-11 [100], probiotics [101] and naloxone [102]. These studies, and those without an intervention, have been critical in identification of novel mechanisms including altered barrier function [68], aberrant extracellular matrix (ECM) signaling [103, 104], enteric glia dysfunction [105] and mucin production [106]. The model has now been modified to study fractionated radiotherapy, with homologous clinical and subclinical features [107]. Most recently, this model was used to characterise ECM dysfunction and microvasculature changes associated with radiation-induced gut injury, a novel aspect of acute mucositis [108, 109]. Despite its prevalent use, this model lacks translatability for chemotherapeutic agents used to treat other solid tumours, and as such, greater research efforts should be diverted to developing a wider range of tumour bearing models. Recently, Mi et al., published a colorectal cancer model, in which dimethyl hydrazine was administered for 10 weeks to Sprague Dawley rats, followed by inoculation with SW480 cells. This model was successfully used to assess simultaneously assess probiotic efficacy in preventing mucositis without compromising chemoefficacy [91] (Table 2).

The introduction of a tumour-bearing mucositis model has been instrumental in advancing our understanding of how tumour burden affects mucositis development, with studies showing pro-inflammatory cytokines released by the tumour not only serve to amplify mucositis, but also affect other parameters intimately involved in mucositis development [110]. For example, it was demonstrated that IL-1 $\beta$  and IL-6, produced by tumour tissue, not only affect food uptake but also energy expenditure leading to cancer cachexia [111]. However implanting tumours into rodents is challenging, often requiring immunosuppression, altering body weight and influencing drug metabolism [110, 112]. As such, while use of a tumour-bearing model of mucositis is important in late-stage drug development, non-tumour bearing models remain an important tool in fundamental mucositis research.

#### **2.1.2.5 Emerging models for next generation anticancer agents**

With the increasing use of non-cytotoxic anticancer agent such as targeted therapies, immunotherapies and monoclonal antibodies, the need to adequately understand their unique mucositis phenotype and underlying mechanisms is critical. Until recently, much of our understanding of the toxicities associated with these therapies has been limited to clinical observation. In 2014, the first **rat model of tyrosine-kinase inhibitor (TKI)-induced diarrhoea** was developed by Bowen and colleagues, using the agent lapatinib [113, 114]. This model utilises a four-week schedule of daily oral lapatinib (50-100 mg/kg) treatment to induce mild-moderate diarrhoea in male albino Wistar rats (Table 2). This schedule achieves an intermittent and repeated presentation of diarrhoea, paralleling the clinic. Of particular interest is the lack of microscopic or macroscopic changes in the jejunum and colon of these rats, highlighting stark differences in the pathobiology of TKI-induced diarrhoea compared to that of 'classical' mucositis. This contradicts findings from previous studies in which mice exposed to gefitinib and elotinib TKIs [115, 116] demonstrated marked abnormalities in intestinal morphology, and thus highlights species-dependent variation in response to. Despite these variations, all models reported positive effects on intestinal morphology or symptomology following co-treatment with the intestinal growth factor glucagon-like peptide-2.

More recently, Van Sebille et al. developed a comparable model of **TKI-induced mucositis using dacomitinib**. 7.5 mg/kg of dacomitinib, administer daily via oral gavage for 21 days was sufficient to induce moderate diarrhoea and associated weight loss [117] (Table 2). In contrast to lapatinib, severe ileal injury was observed, along with changes in MCP-1 expression and intestinal permeability; novel preclinical findings for dacomitinib associated toxicity. This model has subsequently been used to investigate crofelemer, aimed at targeting excessive secretory mechanisms that lead to diarrhoea [118].

#### **2.1.2.2 Sophisticated manipulation in small animal models of mucositis**

More recently, increasingly sophisticated methods have been used to study mucositis pathogenesis including genetic modification, manipulation of the microbiome and elegant targeting of inflammation. **Knockout studies** focusing on toll-like receptors have been most popular of recent, with studies focusing on cytokines (e.g. IL-4), mucin proteins, trefoil factor, p53, p21 and IL-1R, iNOS, IL-10, TLR4, TLR2 and TLR9, informed by immunogenomic analyses and preclinical findings [55, 69, 85, 119-125]. For example, germ-line deletion of TLR4 [69] and MyD88 [122] were shown to be protective against irinotecan-induced gastrointestinal mucositis. Importantly, these effects appear to be drug- and receptor specific, with TLR2 deletion shown to improve irinotecan-

induced mucositis, yet exacerbate MTX-induced mucositis [120]. This highlights the importance of translating findings from animal models in a specific and informed manner.

This is also the case for microbiome-related findings in mucositis. This has undoubtedly been the biggest area of growth for gastrointestinal mucositis, with countless studies now indicating changes in the bacterial composition of animals (and humans) exposed to anticancer agents [126]. Studies aimed at dissecting the causative relationship between the microbiome and mucositis are scarce and somewhat contradictory. Evidence for a direct contribution of the intestinal microbes was demonstrated in **germ-free mice** which were protected against irinotecan-induced mucositis, but lost protection when colonised with a diverse microbiome [65]. This is in stark contrast to studies that utilise **antibiotic-induced microbiome depleted (AIMD) rodents**, which are typically more susceptible to mucositis development.

Inflammatory mechanisms have always been central to mucositis development, demonstrated in some of the earliest animal models. Although based on a sound scientific rationale, targeting of inflammation has been largely underwhelming, with limited clinical translation. More recently however, work using transgenic mice expressing nuclear protein Smad7 in keratinocytes has suggests antagonising TGF-1 and NFkB may be a useful approach in preventing oral mucositis caused by radiotherapy [127]. Similarly, mouse models of chemotherapy-induced mucositis have led to more sophisticated understanding of the immune contributors to mucositis pathogenesis, with blockade of CXCL4 and CXCR3 protecting intestinal tissue from chemotoxicity [128, 129].

## 2.2 Large animal models of mucositis

Although rodents are primarily used for the preclinical study of mucositis, large animal models offer a unique perspective and unparalleled investigation of specific mechanisms of mucositis. Large animals offer greater flexibility in the procedures able to be performed given their size, and are considered to have greater genetic overlap with humans [130]. This is particularly the case for the gastrointestinal metabolome, which is critical when assessing host-microbe/immune interactions [131]. In many models, large animals develop both oral and gastrointestinal manifestations of mucositis. However, these models come at a cost, with housing/husbandry expenses and the cost of consumables significantly higher than that of rodents [110].

The use of **dogs** is scarce in mucositis research, with studies primarily opting for this species when investigating nausea and vomiting associated with mucosal injury [132, 133]. A more commonly used large animal is the pig, given its superior reputation in biomedical research based on higher genetic, anatomical and physiological homology with humans. **Pigs** are also able to receive the complex and clinically relevant supportive care interventions including antibiotics, anti-emetics and analgesics enhancing translational potential [134]. Models of bone marrow transplantation and chemotherapy-induced mucositis have both been developed using minipigs, with both doxorubicin [135] and 5-FU [136] resulting in clinically-comparable symptoms (e.g. diarrhoea, weight loss, sepsis, mortality).

**Young pigs** have also been used to study mucositis induced by non-myeloablative doxorubicin [135, 137], a common conditioning agent used in paediatric leukaemia, developing both clinically and histologically appropriate manifestations of mucositis. This offers a novel platform to study the unique mechanisms of paediatric mucositis and supportive care interventions aimed at childhood cancer. Importantly however, when very young piglets are used, not all features are apparent with

no changes in proinflammatory cytokines, tight junction proteins and digestive enzymes, possibly reflecting the immature and more tolerant state of the infant intestine [110]. These features become more evident when more intense myeloablative regimens are used (busulfan and cyclophosphamide), however this is accompanied by excessive toxicity and high mortality [134].

### **3.0 CHALLENGES IN ANIMAL MODELS OF MUCOSITIS**

Although animal models have been instrumental in advancing our understanding of mucositis, their applicability to the clinic is limited for several reasons and translation must therefore be performed with caution. Firstly, one of the most troublesome symptom of mucositis, particularly affecting the oral cavity, is pain; an inherent difficult parameter measure in both humans and animals. In the case of animal models, pain is a universally challenging parameter to define and objectively quantify [110]. The facial grimace scale has been developed to assess pain-like behaviors in animals [138, 139], and is preferred over more laborious techniques based on stimulus-evoked responses (e.g. von Frey or Hargreaves tests). However, grimace criteria are inherently subjective and require extensive training. Furthermore, the impact of handling on the manifestation of these criteria remains unclear, and as such, studies employing these techniques should consider automated processes such as the Rodent Face Finder [140].

The functional assessment of mucositis also remains challenging in animals models. Although not strictly related to mucositis, rodents do not have an emetogenic reflex and thus the relationship between mucosal toxicity and nausea/vomiting relies on the indirect marker of pica (ingestion of bedding)[141]. Similarly, although rodents develop diarrhoea in many models of mucositis, assessing the severity of diarrhoea relies on the use of semi-quantitative grading systems which are subject to observer subjectivity and bias, and thus requires appropriate blinding. This is further confounded by the lack of universal accepted and validated biomarker, although plasma citrulline now holds promise for mucositis affecting the small intestine [142, 143].

Another issue relating to mucositis research using animals are sex and strain differences in metabolic enzyme profiles, particularly the CYP family. It is critical that any new model be carefully considered to ensure the species chosen displays the correct metabolic capacity for the drug of interest, and that variations in drug clearance (and thus toxicity) be adequately considered. A further disparity between humans and rodents is the composition of the microbiome, having the potential to impact gastrointestinal physiology, and disease phenotypes [144, 145]. Ley et al, in 2005, demonstrated that 85% of murine gut microbiota are not detected in humans [146]. However, this disparity is only observed at the genus level, with humans and rodents both comprising a majority of Bacteroidetes and Firmicutes phyla [145-148], which may still provide a broader gastrointestinal consistency in terms of function. Options to overcome these limitations include the use and colonization of gnotobiotic mice with a desired colony (such as human microbiota) for specific investigations into the host-microbe immune response associated with mucositis. The inherent variability that is seen in laboratory rodents (resulting from husbandry conditions) may, however, be of value in predicting overall patterns that would occur in humans (also displaying inherent individual variability) under similar disease or treatment conditions [149].

Rodent models to investigate the host-microbe interactions that occur, especially over a time course, are essential to elucidate some of the key immunological factors that drive the pathogenesis of mucositis, despite their limitations. A recent *in vitro* study by Vanlancker et al., (2017) showed that neither 5-FU nor SN-38 (active metabolite of irinotecan) have a direct effect on

the microbiota itself, suggesting microbial disturbances are likely to be the result of the host response to these agents [150]. Investigation of these microbial disturbances with a host response in rodent models is therefore still a useful tool in terms of translation, allowing key mechanistic pathways to be determined, and human equivalents investigated.

#### **4.0 CONCLUSION**

Animal research remains a critical aspect in supportive oncology, driving our continued mechanistic understanding of mucositis development and providing an invaluable platform for the assessment of new anti-mucositis agents. To date, animal models have been integral in establishing the 5-phase model of mucositis, and are now becoming increasingly important in defining the unique toxicities associated with newer anticancer agents. Given the highly heterogenous nature of supportive oncology, it is likely that traditional mucositis models will continue to be used to study new interventions, along with increasingly more sophisticated models based on genomic manipulation, careful modification of the microbiome and humanised strains. This will hopefully provide a new wave of data regarding mucositis development and a better understanding of the toxicities of next generation cancer therapies.

## 5.0 KEY POINTS

1. Animal models of mucositis represent clear homology with the clinical setting
2. Golden Syrian hamsters remain the gold-standard model for oral mucositis
3. Gastrointestinal mucositis is readily induced in a variety of animals, including rodents, pigs and dogs via intraperitoneal and intravenous administration
4. Cyclic and multimodal dosing strategies (including radiation, chemotherapy and targeted/immunotherapies) in tumour-bearing animals are encouraged to parallel the clinical scenario
5. Challenges remain in objectively assessing mucositis severity; plasma citrulline shows promise as a clinically translatable biomarker of small intestinal injury

## **6.0 ACKNOWLEDGEMENTS**

No acknowledgements.

**Financial support:** Dr Hannah Wardill is the recipient of an NHMRC CJ Martin Biomedical Research Fellowship.

**Conflicts of interest:** The authors have no conflicts of interest to disclose.

## 7.0 REFERENCES

1. Carlotto A, Hogsett VL, Maiorini EM, *et al.* The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. *Pharmacoeconomics*. 2013;31(9):753-66.
2. Sonis ST. Oral mucositis in cancer therapy. *J Support Oncol*. 2004;2(6 Suppl 3):3-8.
3. Al-Dasooqi N, Sonis ST, Bowen JM, *et al.* Emerging evidence on the pathobiology of mucositis. *Support Care Cancer*. 2013;21(7):2075-83.
4. Andreyev J, Ross P, Donnellan C, *et al.* Guidance on the management of diarrhoea during cancer chemotherapy. *Lancet Oncol*. 2014;15(10):e447-60.
5. Lalla RV, Bowen J, Barasch A, *et al.* MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer*. 2014;120(10):1453-61.
6. Thirion-Delalande C, Gervais F, Fisch C, *et al.* Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products. *PLoS One*. 2017;12(9):e0183398.
7. Montenegro MF, Sundqvist ML, Nihlen C, *et al.* Profound differences between humans and rodents in the ability to concentrate salivary nitrate: Implications for translational research. *Redox Biol*. 2016;10:206-10.
8. Al-Azri AR, Gibson RJ, Bowen JM, *et al.* Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. *J Oral Pathol Med*. 2014.
9. Sonis ST, Tracey C, Shklar G, *et al.* An animal model for mucositis induced by cancer chemotherapy. *Oral Surg Oral Med Oral Pathol*. 1990;69(4):437-43.
10. Ara G, Watkins BA, Zhong H, *et al.* Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. *Int J Radiat Biol*. 2008;84(5):401-12.
11. Sonis ST. *Animal Models of Oral Mucositis Induced by Antineoplastic Drugs and Radiation*. Totoaw, NJ: Humana Press; 2002.
12. Sonis ST. The pathobiology of mucositis. *Nat Rev Cancer*. 2004;4(4):277-84.
13. Watanabe S, Suemaru K, Nakanishi M, *et al.* Assessment of the hamster cheek pouch as a model for radiation-induced oral mucositis, and evaluation of the protective effects of keratinocyte growth factor using this model. *Int J Radiat Biol*. 2014;90(10):884-91.
14. Caluwaerts S, Vandenbroucke K, Steidler L, *et al.* AG013, a mouth rinse formulation of *Lactococcus lactis* secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. *Oral Oncol*. 2010;46(7):564-70.
15. Hwang D, Popat R, Bragdon C, *et al.* Effects of ceramide inhibition on experimental radiation-induced oral mucositis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2005;100(3):321-9.
16. Watkins B, Pouliot K, Fey E, *et al.* Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). *Oral Dis*. 2010;16(7):655-60.
17. Alvarez E, Fey EG, Valax P, *et al.* Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. *Clin Cancer Res*. 2003;9(9):3454-61.
18. Sonis ST, Costa JW, Jr., Evitts SM, *et al.* Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. *Oral Surg Oral Med Oral Pathol*. 1992;74(6):749-55.
19. Sonis ST, Van Vugt AG, Brien JP, *et al.* Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. *Oral Oncol*. 1997;33(1):47-54.
20. Sonis ST, Van Vugt AG, McDonald J, *et al.* Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. *Cytokine*. 1997;9(8):605-12.
21. Dorr W, Spekl K, Farrell CL. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. *Cell Prolif*. 2002;35 Suppl 1:86-92.
22. Dorr W, Brankovic K, Hartmann B. Repopulation in mouse oral mucosa: changes in the effect of dose fractionation. *Int J Radiat Biol*. 2000;76(3):383-90.

23. Dorr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. *Int J Radiat Oncol Biol Phys*. 2002;54(1):245-51.
24. Haagen J, Krohn H, Rollig S, *et al*. Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. *Radiother Oncol*. 2009;92(3):472-6.
25. Secombe KR, Collier JK, Gibson RJ, *et al*. The bidirectional interaction of the gut microbiome and the innate immune system: implications for chemotherapy-induced gastrointestinal toxicity. *Int J Cancer*. 2018.
26. Aricibasi M, Jung A, Heller ED, *et al*. Differences in genetic background influence the induction of innate and acquired immune responses in chickens depending on the virulence of the infecting infectious bursal disease virus (IBDV) strain. *Vet Immunol Immunopathol*. 2010;135(1-2):79-92.
27. Voss G, Dittmer U, Coulibaly C, *et al*. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130. *J Gen Virol*. 1993;74 ( Pt 9):1757-63.
28. Blagojevic V, Kovacevic-Jovanovic V, Curuvija I, *et al*. Rat strain differences in peritoneal immune cell response to selected gut microbiota: A crossroad between tolerance and autoimmunity? *Life Sci*. 2018;197:147-57.
29. Gibson RJ, Bowen JM, Alvarez E, *et al*. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. *Chemotherapy*. 2007;53(5):360-9.
30. Kuiken NS, Rings EH, Havinga R, *et al*. Effect of minimal enteral feeding on recovery in a methotrexate-induced gastrointestinal mucositis rat model. *Support Care Cancer*. 2016;24(3):1357-64.
31. Fijlstra M, Schierbeek H, Voortman G, *et al*. Continuous enteral administration can enable normal amino acid absorption in rats with methotrexate-induced gastrointestinal mucositis. *J Nutr*. 2012;142(11):1983-90.
32. Fijlstra M, Rings EH, van Dijk TH, *et al*. Continuous enteral administration can overcome the limited capacity to absorb glucose in rats with methotrexate-induced gastrointestinal mucositis. *Support Care Cancer*. 2013;21(3):863-71.
33. Kuiken NS, Rings EH, Havinga R, *et al*. Effect of Oral Insulin on the Severity and Recovery of Methotrexate-Induced Gastrointestinal Mucositis in the Rat. *J Pediatr Gastroenterol Nutr*. 2017;64(2):e27-e32.
34. Kuiken NSS, Rings E, Alffenaar JC, *et al*. Tumor Necrosis Factor-Alpha Inhibitor Etanercept Does Not Alter Methotrexate-Induced Gastrointestinal Mucositis in Rats. *J Pediatr Gastroenterol Nutr*. 2017;65(2):e28-e34.
- \*\* Most recent publication utilising plasma citrulline as a biomarker of MTX induced mucositis.
35. Kuiken NSS, Rings E, Blijlevens NMA, *et al*. Biomarkers and non-invasive tests for gastrointestinal mucositis. *Support Care Cancer*. 2017;25(9):2933-41.
36. Sukhotnik I, Geyer T, Pollak Y, *et al*. The role of Wnt/beta-catenin signaling in enterocyte turnover during methotrexate-induced intestinal mucositis in a rat. *PLoS One*. 2014;9(11):e110675.
37. Sukhotnik I, Mogilner JG, Shteinberg D, *et al*. Leptin accelerates enterocyte turnover during methotrexate-induced intestinal mucositis in a rat. *Cancer Biol Ther*. 2009;8(10):899-906.
38. Koppelman T, Pollak Y, Mogilner J, *et al*. Dietary L-arginine supplementation reduces Methotrexate-induced intestinal mucosal injury in rat. *BMC Gastroenterol*. 2012;12:41.
39. Sukhotnik I, Mogilner JG, Karry R, *et al*. Effect of oral glutamine on enterocyte turnover during methotrexate-induced mucositis in rats. *Digestion*. 2009;79(1):5-13.
40. Sukhotnik I, Shteinberg D, Ben Lulu S, *et al*. Effect of transforming growth factor-alpha on enterocyte apoptosis is correlated with EGF receptor expression along the villus-crypt axis during methotrexate-induced intestinal mucositis in a rat. *Apoptosis*. 2008;13(11):1344-55.
41. Shaoul R, Moati D, Schwartz B, *et al*. Effect of Pomegranate Juice on Intestinal Recovery Following Methotrexate-Induced Intestinal Damage in a Rat Model. *J Am Coll Nutr*. 2018;37(5):406-14.
42. Sukhotnik I, Moati D, Shaoul R, *et al*. Quercetin prevents small intestinal damage and enhances intestinal recovery during methotrexate-induced intestinal mucositis of rats. *Food Nutr Res*. 2018;62.

43. Sukhotnik I, Shehadeh N, Coran AG, *et al.* Oral insulin enhances cell proliferation and decreases enterocyte apoptosis during methotrexate-induced mucositis in the rat. *J Pediatr Gastroenterol Nutr.* 2008;47(2):115-22.
44. Carneiro-Filho BA, Lima IP, Araujo DH, *et al.* Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. *Dig Dis Sci.* 2004;49(1):65-72.
45. de Araujo AA, Borba PB, de Souza FH, *et al.* In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. *Biol Pharm Bull.* 2015;38(5):746-52.
46. Francois M, Takagi K, Legrand R, *et al.* Increased Ghrelin but Low Ghrelin-Reactive Immunoglobulins in a Rat Model of Methotrexate Chemotherapy-Induced Anorexia. *Front Nutr.* 2016;3:23.
47. Mashtoub S, Lampton LS, Eden GL, *et al.* Emu Oil Combined with Lyprinol Reduces Small Intestinal Damage in a Rat Model of Chemotherapy-Induced Mucositis. *Nutr Cancer.* 2016;68(7):1171-80.
48. Whittaker AL, Zhu Y, Howarth GS, *et al.* Effects of commercially produced almond by-products on chemotherapy-induced mucositis in rats. *World J Gastrointest Pathophysiol.* 2017;8(4):176-87.
49. Whitford EJ, Cummins AG, Butler RN, *et al.* Effects of *Streptococcus thermophilus* TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU). *Cancer Biol Ther.* 2009;8(6):505-11.
50. Clarke J, Butler R, Howarth G, *et al.* Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. *Oral Oncol.* 2002;38(5):478-85.
51. Cheah KY, Howarth GS, Yazbeck R, *et al.* Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. *Cancer Biol Ther.* 2009;8(4):382-90.
52. Wright TH, Yazbeck R, Lymn KA, *et al.* The herbal extract, Iberogast, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis. *Cancer Biol Ther.* 2009;8(10):923-9.
53. Bajic JE, Eden GL, Lampton LS, *et al.* Rhubarb extract partially improves mucosal integrity in chemotherapy-induced intestinal mucositis. *World J Gastroenterol.* 2016;22(37):8322-33.
54. Chartier LC, Howarth GS, Lawrance IC, *et al.* Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer. *Dig Dis Sci.* 2018;63(1):135-45.
- \*\* Study highlighting use of rodent colonoscopy in preclinical models of intestinal disease.
55. Jain U, Midgen CA, Woodruff TM, *et al.* Properdin deficiency protects from 5-fluorouracil-induced small intestinal mucositis in a complement activation-independent, interleukin-10-dependent mechanism. *Clin Exp Immunol.* 2017;188(1):36-44.
56. Zhang S, Liu Y, Xiang D, *et al.* Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury. *Biomed Pharmacother.* 2018;106:910-6.
- \*\* Dose-response study for 5-FU induced mucositis in mice.
57. Yeung CY, Chan WT, Jiang CB, *et al.* Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model. *PLoS One.* 2015;10(9):e0138746.
58. Justino PF, Melo LF, Nogueira AF, *et al.* Treatment with *Saccharomyces boulardii* reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. *Br J Nutr.* 2014;111(9):1611-21.
59. Kim HJ, Kim JH, Moon W, *et al.* Rebamipide attenuates 5-Fluorouracil-induced small intestinal mucositis in a mouse model. *Biol Pharm Bull.* 2015;38(2):179-83.
60. Wu Z, Han X, Qin S, *et al.* Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. *Biomed Pharmacother.* 2010;64(9):589-93.
61. Matsumoto K, Nakajima T, Sakai H, *et al.* Increased expression of 5-HT3 and NK 1 receptors in 5-fluorouracil-induced mucositis in mouse jejunum. *Dig Dis Sci.* 2013;58(12):3440-51.
62. Yasuda M, Kato S, Yamanaka N, *et al.* 5-HT(3) receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. *Br J Pharmacol.* 2013;168(6):1388-400.
63. Huang T, HC C, YL L, *et al.* Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. *Biochem Biophys Res Commun.* 2009;389(4):5.

64. Di Paolo A, Bocci G, Danesi R, *et al.* Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. *Curr Clin Pharmacol.* 2006;1(3):311-23.
65. Pedroso SH, Vieira AT, Bastos RW, *et al.* Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. *Microbiology.* 2015.
66. Takasuna K, Hagiwara T, Hirohashi M, *et al.* Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. *Cancer Res.* 1996;56(16):3752-7.
67. Kurita A, Kado S, Matsumoto T, *et al.* Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of beta-glucuronidase activity in intestinal lumen. *Cancer Chemother Pharmacol.* 2011;67(1):201-13.
68. Wardill HR, Bowen JM, Al-Dasooqi N, *et al.* Irinotecan disrupts tight junction proteins within the gut : implications for chemotherapy-induced gut toxicity. *Cancer Biol Ther.* 2014;15(2):236-44.
69. Wardill HR, Gibson RJ, Van Sebille YZ, *et al.* Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. *Mol Cancer Ther.* 2016;15(6):1376-86.
70. Gibson RJ, Coller JK, Wardill HR, *et al.* Chemotherapy-induced gut toxicity and pain: involvement of TLRs. *Support Care Cancer.* 2015.
71. Mathijssen RH, Verweij J, de Bruijn P, *et al.* Effects of St. John's wort on irinotecan metabolism. *J Natl Cancer Inst.* 2002;94(16):1247-9.
72. Birdsall TC. St. John's wort and irinotecan-induced diarrhea. *Toxicol Appl Pharmacol.* 2007;220(1):108; author reply 9-10.
73. Hu ZP, Yang XX, Chan SY, *et al.* St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. *Toxicol Appl Pharmacol.* 2006;216(2):225-37.
74. Hu Z, Yang X, Ho PC, *et al.* St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. *Pharm Res.* 2005;22(6):902-14.
75. Bastos RW, Pedroso SH, Vieira AT, *et al.* *Saccharomyces cerevisiae* UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis. *Benef Microbes.* 2016;7(4):549-57.
76. Arifa RDN, Paula TP, Madeira MFM, *et al.* The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan. *Pharmacol Res.* 2016;107:102-10.
77. Mathijssen RH, van Alphen RJ, Verweij J, *et al.* Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). *Clin Cancer Res.* 2001;7(8):2182-94.
78. Li J, Yu Q, Fu S, *et al.* A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. *J Cancer Res Clin Oncol.* 2016;142(7):1621-8.
79. McQuade RM, Stojanovska V, Stavely R, *et al.* Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. *Br J Pharmacol.* 2018;175(4):656-77.
- \*\* Validated model of oxaliplatin induced gastrointestian dysfunction.
80. Stojanovska V, McQuade RM, Fraser S, *et al.* Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. *PLoS One.* 2018;13(6):e0198359.
81. McQuade RM, Carbone SE, Stojanovska V, *et al.* Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. *Br J Pharmacol.* 2016;173(24):3502-21.
82. Stojanovska V, McQuade RM, Miller S, *et al.* Effects of Oxaliplatin Treatment on the Myenteric Plexus Innervation and Glia in the Murine Distal Colon. *J Histochem Cytochem.* 2018:22155418774755.
83. Wang H, Brook CL, Whittaker AL, *et al.* Effects of *Streptococcus thermophilus* TH-4 in a rat model of doxorubicin-induced mucositis. *Scand J Gastroenterol.* 2013;48(8):959-68.
84. de Koning BA, Lindenbergh-Kortleve DJ, Pieters R, *et al.* Alterations in epithelial and mesenchymal intestinal gene expression during doxorubicin-induced mucositis in mice. *Dig Dis Sci.* 2007;52(8):1814-25.
85. Kaczmarek A, Brinkman BM, Heyndrickx L, *et al.* Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. *J Pathol.* 2012;226(4):598-608.

86. Chen YH, Lee YT, Wen CC, *et al.* Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish. *Onco Targets Ther.* 2014;7:1169-75.
87. Wang YH, Chen YH, Lin YJ, *et al.* Spatiotemporal expression of zebrafish keratin 18 during early embryogenesis and the establishment of a keratin 18:RFP transgenic line. *Gene Expr Patterns.* 2006;6(4):335-9.
88. Ding YJ, Chen YH. Developmental nephrotoxicity of aristolochic acid in a zebrafish model. *Toxicol Appl Pharmacol.* 2012;261(1):59-65.
89. Pereira VB, Melo AT, Assis-Junior EM, *et al.* A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. *Cancer Chemother Pharmacol.* 2016;77(2):323-32.
90. Wang X, Gao J, Qian L, *et al.* Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis. *Anticancer Drugs.* 2015;26(1):35-45.
91. Mi H, Dong Y, Zhang B, *et al.* Bifidobacterium Infantis Ameliorates Chemotherapy-Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats. *Cell Physiol Biochem.* 2017;42(6):2330-41.
92. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. *Lancet Oncol.* 2007;8(11):1007-17.
93. Erlandsson J, Holm T, Pettersson D, *et al.* Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. *Lancet Oncol.* 2017;18(3):336-46.
94. Rotolo JA, Kolesnick R, Fuks Z. Timing of lethality from gastrointestinal syndrome in mice revisited. *Int J Radiat Oncol Biol Phys.* 2009;73(1):6-8.
95. Bull C, Malipatlolla D, Kalm M, *et al.* A novel mouse model of radiation-induced cancer survivorship diseases of the gut. *Am J Physiol Gastrointest Liver Physiol.* 2017;313(5):G456-G66.
- \*\* Preclinical mouse model of radiation induced gastrointestinal mucositis.
96. Vanhoecke B, Bateman E, Mayo B, *et al.* Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. *Exp Biol Med (Maywood).* 2015;240(6):725-41.
97. Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. *Int J Cancer.* 2005;116(3):464-70.
98. Gibson RJ, Keefe DM, Clarke JM, *et al.* The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. *Cancer Chemother Pharmacol.* 2002;50(1):53-8.
99. Gibson RJ, Stringer AM, Bowen JM, *et al.* Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. *Cancer Biol Ther.* 2007;6(4):541-7.
100. Gibson RJ, Keefe DM, Thompson FM, *et al.* Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. *Dig Dis Sci.* 2002;47(12):2751-7.
101. Bowen JM, Stringer AM, Gibson RJ, *et al.* VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. *Cancer Biol Ther.* 2007;6(9):1449-54.
102. Collier JK, Bowen JM, Ball IA, *et al.* Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. *Cancer Chemother Pharmacol.* 2017;79(2):431-4.
103. Al-Dasooqi N, Bowen J, Bennett C, *et al.* Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study. *Support Care Cancer.* 2017;25(2):391-8.
104. Al-Dasooqi N, Gibson RJ, Bowen JM, *et al.* Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. *Exp Biol Med (Maywood).* 2010;235(10):1244-56.
105. Thorpe D, Stringer A, Butler R. Chemotherapy-induced mucositis: the role of mucin secretion and regulation, and the enteric nervous system. *Neurotoxicology.* 2013;38:101-5.
106. Stringer AM, Gibson RJ, Logan RM, *et al.* Irinotecan-induced mucositis is associated with changes in intestinal mucins. *Cancer Chemother Pharmacol.* 2009;64(1):123-32.
107. Yeoh AS, Gibson RJ, Yeoh EE, *et al.* A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. *Mol Cancer Ther.* 2007;6(8):2319-27.

108. Stansborough RL, Al-Dasooqi N, Bateman EH, *et al.* Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo. *Support Care Cancer*. 2018.
109. Stansborough RL, Bateman EH, Al-Dasooqi N, *et al.* Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFbeta), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. *Int J Radiat Biol*. 2018;94(7):645-55.
110. Sangild PT, Shen RL, Pontoppidan P, *et al.* Animal models of chemotherapy-induced mucositis: translational relevance and challenges. *Am J Physiol Gastrointest Liver Physiol*. 2018;314(2):G231-G46.
111. Bauer J, Jurgens H, Fruhwald MC. Important aspects of nutrition in children with cancer. *Adv Nutr*. 2011;2(2):67-77.
112. Bateman E, Bowen J, Stringer A, *et al.* Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. *Nutrients*. 2013;5(10):3948-63.
113. Bowen JM. Development of the rat model of lapatinib-induced diarrhoea. *Scientifica (Cairo)*. 2014;2014:194185.
114. Bowen JM, Mayo BJ, Plews E, *et al.* Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. *Cancer Chemother Pharmacol*. 2014;74(3):617-27.
115. Hare KJ, Hartmann B, Kissow H, *et al.* The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. *Clin Cancer Res*. 2007;13(17):5170-5.
116. Rasmussen AR, Viby NE, Hare KJ, *et al.* The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. *Dig Dis Sci*. 2010;55(10):2785-96.
117. Van Seville YZA, Gibson RJ, Wardill HR, *et al.* Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. *Int J Cancer*. 2017;140(12):2820-9.
- \*\* First and only preclinical rat model of dacomitinib-induced intestinal injury.**
118. Van Seville YZA, Gibson RJ, Wardill HR, *et al.* Dacomitinib-induced diarrhea: Targeting chloride secretion with crolemer. *Int J Cancer*. 2018;142(2):369-80.
119. Wardill HR, Bowen JM, Van Seville YZ, *et al.* TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. *Mol Cancer Ther*. 2016;15(11):2767-79.
120. Frank M, Hennenberg EM, Eyking A, *et al.* TLR signaling modulates side effects of anticancer therapy in the small intestine. *J Immunol*. 2015;194(4):1983-95.
121. Soares PM, Mota JM, Souza EP, *et al.* Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. *Cytokine*. 2013;61(1):46-9.
122. Wong DV, Lima-Junior RC, Carvalho CB, *et al.* The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis. *PLoS One*. 2015;10(10):e0139985.
123. Wang X, Zhu S, Qian L, *et al.* IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.). *Pharmacol Res*. 2014;82:21-33.
124. Leitao RF, Brito GA, Oria RB, *et al.* Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. *BMC Gastroenterol*. 2011;11:90.
125. de Koning BA, Sluis M, Lindenbergh-Kortleve DJ, *et al.* Methotrexate-induced mucositis in mucin 2-deficient mice. *J Cell Physiol*. 2007;210(1):144-52.
126. Alexander JL, Wilson ID, Teare J, *et al.* Gut microbiota modulation of chemotherapy efficacy and toxicity. *Nat Rev Gastroenterol Hepatol*. 2017;14(6):356-65.
127. Han G, Bian L, Li F, *et al.* Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. *Nat Med*. 2013;19(4):421-8.
128. Gao J, Gao J, Qian L, *et al.* Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil. *Cancer Biol Ther*. 2014;15(8):982-91.
129. Lu H, Liu H, Wang J, *et al.* The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution. *J Cancer Res Clin Oncol*. 2015;141(6):983-92.

130. Schook LB, Collares TV, Darfour-Oduro KA, *et al.* Unraveling the swine genome: implications for human health. *Annu Rev Anim Biosci.* 2015;3:219-44.
131. Xiao L, Estelle J, Kiillerich P, *et al.* A reference gene catalogue of the pig gut microbiome. *Nat Microbiol.* 2016:16161.
132. Appelbaum FR, Deeg HJ, Storb R, *et al.* Marrow transplant studies in dogs with malignant lymphoma. *Transplantation.* 1985;39(5):499-504.
133. Gupta YK, Sharma SS. Antiemetic activity of antioxidants against cisplatin-induced emesis in dogs. *Environ Toxicol Pharmacol.* 1996;1(3):179-84.
134. Pontoppidan PL, Shen RL, Petersen BL, *et al.* Intestinal response to myeloablative chemotherapy in piglets. *Exp Biol Med (Maywood).* 2014;239(1):94-104.
135. Martin J, Howard SC, Pillai A, *et al.* The weaned pig as a model for Doxorubicin-induced mucositis. *Chemotherapy.* 2014;60(1):24-36.
136. Manzano M, Bueno P, Rueda R, *et al.* Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model. *Chemotherapy.* 2007;53(5):344-55.
137. Shen RL, Pontoppidan PE, Rathe M, *et al.* Milk diets influence doxorubicin-induced intestinal toxicity in piglets. *Am J Physiol Gastrointest Liver Physiol.* 2016;311(2):G324-33.
138. Sotocinal SG, Sorge RE, Zaloum A, *et al.* The Rat Grimace Scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. *Mol Pain.* 2011;7:55.
139. De Rantere D, Schuster CJ, Reimer JN, *et al.* The relationship between the Rat Grimace Scale and mechanical hypersensitivity testing in three experimental pain models. *Eur J Pain.* 2015.
140. Deuis JR, Dvorakova LS, Vetter I. **Methods Used to Evaluate Pain Behaviors in Rodents.** *Front Mol Neurosci.* 2017;10:284.
- \*\* **Commentary addressing various methods of assessing pain in rodents.**
141. Bowen JM, Gibson RJ, Keefe DM. Animal models of mucositis: implications for therapy. *J Support Oncol.* 2011;9(5):161-8.
142. Barzal JA, Szczylik C, Rzepecki P, *et al.* Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage. *Acta Biochim Pol.* 2014;61(4):615-31.
143. Fijlstra M, Rings EH, Verkade HJ, *et al.* Lactose maldigestion during methotrexate-induced gastrointestinal mucositis in a rat model. *Am J Physiol Gastrointest Liver Physiol.* 2011;300(2):G283-91.
144. Hugenholtz F, de Vos WM. Mouse models for human intestinal microbiota research: a critical evaluation. *Cell Mol Life Sci.* 2018;75(1):149-60.
145. Franklin CL, Ericsson AC. Microbiota and reproducibility of rodent models. *Lab Anim (NY).* 2017;46(4):114-22.
146. Ley RE, Backhed F, Turnbaugh P, *et al.* Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A.* 2005;102(31):11070-5.
147. Ley RE, Peterson DA, Gordon JL. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell.* 2006;124(4):837-48.
148. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. *Clin Infect Dis.* 2007;44(2):256-62.
149. Wardill HR, Bowen JM, Van Sebille YZA, *et al.* Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. *Gut.* 2017;66(10):1869-71.
150. Vanlancker E, Vanhoecke B, Stringer A, *et al.* 5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro. *PeerJ.* 2017;5:e4017.